Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter
Atrial Flutter
About this trial
This is an interventional treatment trial for Atrial Flutter
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- ECG documented paroxysmal or persistent AFL
- No prior documented history of AF
- Patient undergoing RFA of AFL.
- No indication (other than AFL) for continued anticoagulation with warfarin.
- No existing implantable cardiac device (pacemaker, defibrillator, cardiac resynchronization therapy device)
Exclusion Criteria:
- A history of atrial fibrillation
- Previous AF ablation procedure
- Congestive heart failure
- Left Ventricle ejection fraction less than 35%
- Unwillingness to participate
Sites / Locations
- State Research Institute of Circulation PathologyRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
RFA+BT injection
RFA
Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a flow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).